Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
Cart
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Home
Journals
Acta Pharmaceutica
Volume 71 (2021): Issue 2 (June 2021)
Open Access
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies
Safa Daoud
Safa Daoud
,
Shada J. Alabed
Shada J. Alabed
and
Lina A. Dahabiyeh
Lina A. Dahabiyeh
| Nov 04, 2020
Acta Pharmaceutica
Volume 71 (2021): Issue 2 (June 2021)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Nov 04, 2020
Page range:
163 - 174
Accepted:
Jun 02, 2020
DOI:
https://doi.org/10.2478/acph-2021-0016
Keywords
COVID-19
,
main protease
,
pharmacophore
,
structure-based modeling
,
docking study
,
remdesivir
,
repurposing
© 2021 Safa Daoud et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Safa Daoud
Department of Pharmaceutical, Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science, Private University
Amman, Jordan
Shada J. Alabed
Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan
Amman, Jordan
Lina A. Dahabiyeh
Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan
Amman, Jordan